大黄人参方缓解晚期消化道恶性肿瘤患者化疗副反应及提高疗效的临床研究

Clinical observation of Dahuang- renshen formula on chemotherapy side effects reduction and therapeutic efficiency improvement in patients with advanced gastrointestinal carcinoma

目的观察大黄人参方联合化疗治疗晚期消化道恶性肿瘤患者的有效性和安全性。方法将154例晚期消化道恶性肿瘤患者随机分为2组。对照组77例仅予常规化疗,治疗组77例在化疗基础上加用大黄人参方口服。观察2组客观疗效、生活质量、生存期及不良反应。结果治疗组临床获益率(88.31%)高于对照组(74.32%,P<0.05);治疗组治疗后卡氏评分(KPS)评分好转率、食欲增加率及体质量增加率均高于对照组,差异均有统计学意义(P<0.05);治疗组白细胞减少、恶心呕吐、腹泻、肝肾功能损害及脱发不良反应发生率低对照组(P<0.05);治疗组无进展生存时间(PFS)较对照组明显延长(P<0.05)。结论大黄人参方联合化疗治疗晚期消化道恶性肿瘤能够提高患者临床获益率,改善生活质量,延长生存期,减轻化疗毒副反应。

Objective To observe the efficacy and safety of Dahuang - renshen formula combined with chemotherapy on the treatment of advanced gastrointestinal carcinoma. Methods 154 advanced gastrointestinal carcinoma patients were randomly divided into two groups. 77 patients in control group were treated by routine chemotherapy. 77 patients in treatment group were treated by oral Dahuang - renshen formula on the basis of chemotherapy. The objective response, quality of life, survival time and adverse reaction were observed in two groups. Results The clinical benefit rate in treatment group （88.31%） was superior to that in control group （74.32%, P 〈0.05）. The improvement rates of Karnofsky perforemance status （KPS） score, appetite and body mass after treatment were in treatment group were higher than those in control group （ P 〈 0.05）. The adverse reaction rates of leucopenia, nausea, vomiting, diarrhea, liver and kidney functional lesion and hair loss in treatment group were lower than those in control group （ P 〈 0. 05 ）. The progression- free survival （PFS） in treatment group was obviously longer than that in control group （ P 〈0. 05 ）. Conclusion Dahuang - renshen formula combined with chemotherapy on the treatment of advanced gastrointestinal carcinoma can enhance clinical benefit rate, improve quality of life, prolong survival time, and relieve the side effect and adverse reaction of chemotherapy.